228 related articles for article (PubMed ID: 36152932)
1. Engineering nucleotide sugar synthesis pathways for independent and simultaneous modulation of N-glycan galactosylation and fucosylation in CHO cells.
Prabhu A; Shanmugam D; Gadgil M
Metab Eng; 2022 Nov; 74():61-71. PubMed ID: 36152932
[TBL] [Abstract][Full Text] [Related]
2. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
3. Generation of FX
Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B
Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555
[TBL] [Abstract][Full Text] [Related]
4. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
[TBL] [Abstract][Full Text] [Related]
5. A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.
Roy G; Martin T; Barnes A; Wang J; Jimenez RB; Rice M; Li L; Feng H; Zhang S; Chaerkady R; Wu H; Marelli M; Hatton D; Zhu J; Bowen MA
MAbs; 2018 Apr; 10(3):416-430. PubMed ID: 29400603
[TBL] [Abstract][Full Text] [Related]
6. Fucosyltransferases produce N-glycans containing core l-galactose.
Ohashi H; Ohashi T; Kajiura H; Misaki R; Kitamura S; Fujiyama K
Biochem Biophys Res Commun; 2017 Jan; 483(1):658-663. PubMed ID: 27993676
[TBL] [Abstract][Full Text] [Related]
7. An investigation of intracellular glycosylation activities in CHO cells: effects of nucleotide sugar precursor feeding.
Wong NS; Wati L; Nissom PM; Feng HT; Lee MM; Yap MG
Biotechnol Bioeng; 2010 Oct; 107(2):321-36. PubMed ID: 20506284
[TBL] [Abstract][Full Text] [Related]
8. Media supplementation for targeted manipulation of monoclonal antibody galactosylation and fucosylation.
Wells E; Song L; Greer M; Luo Y; Kurian V; Ogunnaike B; Robinson AS
Biotechnol Bioeng; 2020 Nov; 117(11):3310-3321. PubMed ID: 32662879
[TBL] [Abstract][Full Text] [Related]
9. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
10. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
11. Facile Modulation of Antibody Fucosylation with Small Molecule Fucostatin Inhibitors and Cocrystal Structure with GDP-Mannose 4,6-Dehydratase.
Allen JG; Mujacic M; Frohn MJ; Pickrell AJ; Kodama P; Bagal D; San Miguel T; Sickmier EA; Osgood S; Swietlow A; Li V; Jordan JB; Kim KW; Rousseau AC; Kim YJ; Caille S; Achmatowicz M; Thiel O; Fotsch CH; Reddy P; McCarter JD
ACS Chem Biol; 2016 Oct; 11(10):2734-2743. PubMed ID: 27434622
[TBL] [Abstract][Full Text] [Related]
12. Production of afucosylated antibodies in CHO cells by coexpression of an anti-FUT8 intrabody.
Joubert S; Guimond J; Perret S; Malenfant F; Elahi SM; Marcil A; Parat M; Gilbert M; Lenferink AEG; Baardsnes J; Durocher Y
Biotechnol Bioeng; 2022 Aug; 119(8):2206-2220. PubMed ID: 35509261
[TBL] [Abstract][Full Text] [Related]
13. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues.
Raju TS; Briggs JB; Chamow SM; Winkler ME; Jones AJ
Biochemistry; 2001 Jul; 40(30):8868-76. PubMed ID: 11467948
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial genome and protein engineering yields monoclonal antibodies with hypergalactosylation from CHO cells.
Chung CY; Wang Q; Yang S; Ponce SA; Kirsch BJ; Zhang H; Betenbaugh MJ
Biotechnol Bioeng; 2017 Dec; 114(12):2848-2856. PubMed ID: 28926673
[TBL] [Abstract][Full Text] [Related]
15. Zinc supplementation decreases galactosylation of recombinant IgG in CHO cells.
Prabhu A; Gadre R; Gadgil M
Appl Microbiol Biotechnol; 2018 Jul; 102(14):5989-5999. PubMed ID: 29749563
[TBL] [Abstract][Full Text] [Related]
16. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
17. Supplementing glycosylation: A review of applying nucleotide-sugar precursors to growth medium to affect therapeutic recombinant protein glycoform distributions.
Blondeel EJM; Aucoin MG
Biotechnol Adv; 2018; 36(5):1505-1523. PubMed ID: 29913209
[TBL] [Abstract][Full Text] [Related]
18. CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation.
Grainger RK; James DC
Biotechnol Bioeng; 2013 Nov; 110(11):2970-83. PubMed ID: 23737295
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
Mishra N; Spearman M; Donald L; Perreault H; Butler M
J Biotechnol; 2020; 324S():100015. PubMed ID: 34154738
[TBL] [Abstract][Full Text] [Related]
20. A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies.
Gilormini PA; Thota VN; Fers-Lidou A; Ashmus RA; Nodwell M; Brockerman J; Kuo CW; Wang Y; Gray TE; Nitin ; McDonagh AW; Guu SY; Ertunc N; Yeo D; Zandberg WF; Khoo KH; Britton R; Vocadlo DJ
Proc Natl Acad Sci U S A; 2024 Jul; 121(27):e2314026121. PubMed ID: 38917011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
